NASDAQ:MAPP - MAP Pharmaceuticals Stock Price, Price Target & More

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About MAP Pharmaceuticals (NASDAQ:MAPP)

MAP Pharmaceuticals logoMAP Pharmaceuticals, Inc., incorporated on July 3, 2003, is a development-stage company. As of December 31, 2011, the Company was focusing to advance its product candidate, LEVADEX (MAP0004) orally inhaled migraine therapy, which is an orally inhaled version of dihydroergotamine mesylate (DHE), for the acute treatment of migraine. The Company had completed clinical development for LEVADEX in 2011 and submitted its New Drug Application (NDA) to the United States Food and Drug Administration (FDA). LEVADEX is at-home therapy in development that patients self-administer using its hand-held TEMPO inhaler. Effective March 1, 2013, Allergen Inc acquired the entire share capital of MAP Pharmaceuticals Inc.

Receive MAPP News and Ratings via Email

Sign-up to receive the latest news and ratings for MAPP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A

How to Become a New Pot Stock Millionaire

MAP Pharmaceuticals (NASDAQ:MAPP) Frequently Asked Questions

What is MAP Pharmaceuticals' stock symbol?

MAP Pharmaceuticals trades on the NASDAQ under the ticker symbol "MAPP."

Who are some of MAP Pharmaceuticals' key competitors?

Has MAP Pharmaceuticals been receiving favorable news coverage?

News coverage about MAPP stock has been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. MAP Pharmaceuticals earned a media sentiment score of 0.16 on Accern's scale. They also assigned media coverage about the healthcare company an impact score of 47.19 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of MAP Pharmaceuticals?

Shares of MAPP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact MAP Pharmaceuticals?

MAP Pharmaceuticals' mailing address is 2525 Dupont Dr, IRVINE, CA 92612-1531, United States. The healthcare company can be reached via phone at +1-302-6587581.

MarketBeat Community Rating for MAP Pharmaceuticals (MAPP)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  71 (Vote Outperform)
Underperform Votes:  54 (Vote Underperform)
Total Votes:  125
MarketBeat's community ratings are surveys of what our community members think about MAP Pharmaceuticals and other stocks. Vote "Outperform" if you believe MAPP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MAPP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MAP Pharmaceuticals (NASDAQ:MAPP) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 4/22/2016 forward)


MAP Pharmaceuticals (NASDAQ:MAPP) Earnings History and Estimates Chart

Earnings by Quarter for MAP Pharmaceuticals (NASDAQ:MAPP)

MAP Pharmaceuticals (NASDAQ MAPP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2012Q3 2012($0.39)($0.38)ViewN/AView Earnings Details
7/24/2012Q2 2012($0.43)($0.43)ViewN/AView Earnings Details
5/4/2012Q1 2012($0.40)($0.49)ViewN/AView Earnings Details
3/29/2012Q4 2011($0.30)($0.45)ViewN/AView Earnings Details
11/8/2011Q3 2011$0.35$0.36ViewN/AView Earnings Details
8/4/2011Q2 2011($0.38)($0.28)ViewN/AView Earnings Details
5/3/2011Q1 2011($0.39)$0.56ViewN/AView Earnings Details
3/1/2011Q4 2010($0.44)($0.46)ViewN/AView Earnings Details
11/5/2010Q3 2010($0.45)($0.53)ViewN/AView Earnings Details
8/3/2010Q2 2010($0.48)($0.47)ViewN/AView Earnings Details
5/4/2010Q1 2010($0.52)($0.54)ViewN/AView Earnings Details
3/2/2010Q4 2009($0.41)($0.54)ViewN/AView Earnings Details
11/5/2009Q3 2009$0.94$0.80ViewN/AView Earnings Details
8/3/2009Q2 2009($0.43)($0.24)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.80)($0.48)ViewN/AView Earnings Details
3/2/2009Q4 2008($0.97)($1.07)ViewN/AView Earnings Details
11/12/2008Q3 2008($0.88)($1.00)ViewN/AView Earnings Details
8/12/2008Q2 2008($0.82)($0.81)ViewN/AView Earnings Details
5/12/2008Q1 2008($0.76)($0.71)ViewN/AView Earnings Details
2/28/2008Q4 2007($0.45)($0.76)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


MAP Pharmaceuticals (NASDAQ:MAPP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

MAP Pharmaceuticals (NASDAQ MAPP) Insider Trading and Institutional Ownership History

Insider Trading History for MAP Pharmaceuticals (NASDAQ:MAPP)

MAP Pharmaceuticals (NASDAQ MAPP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)


MAP Pharmaceuticals (NASDAQ MAPP) News Headlines

No headlines for this company have been tracked by

SEC Filings

MAP Pharmaceuticals (NASDAQ:MAPP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


MAP Pharmaceuticals (NASDAQ:MAPP) Income Statement, Balance Sheet and Cash Flow Statement


MAP Pharmaceuticals (NASDAQ MAPP) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.